Drug interactions
Encorafenib + Indacaterol-glycopyrronium
Severity: Moderate
Encorafenib and Indacaterol-glycopyrronium: moderate interaction.
Last updated
For healthcare professionals — reference only. This page is a brief summary, not medical advice and not a substitute for official labeling or clinical judgement. Always verify before prescribing or dispensing.
Summary
Encorafenib can prolong the QT interval in a dose-dependent way. Indacaterol may add to repolarization effects and reduce potassium, so arrhythmia risk may increase.
What this interaction means in plain words
Encorafenib and Indacaterol-glycopyrronium can affect each other. The combination is often manageable, but it may need a change of dose, a change of timing, or extra checks while both are taken.
Encorafenib belongs to Oncology; Indacaterol-glycopyrronium belongs to Respiratory.
Why it happens
Additive QT prolongation with beta2-agonist related hypokalemia.
What to do
Monitor ECG and electrolytes during encorafenib therapy, and correct potassium and magnesium abnormalities. Reduce or hold encorafenib if QTc becomes markedly prolonged.
What to ask your pharmacist
- Should I take them at different times of day?
- Does the dose of either medicine need to change?
- Is there anything I should avoid, such as alcohol or certain foods, while on both?
Pro+ members
Unlock the full page
Create an account and start a Pro+ trial to unlock the full management advice for Encorafenib and Indacaterol-glycopyrronium, the additional notes, the evidence detail and the whole-prescription interaction checker.
- Full clinical management advice
- Additional notes
- Evidence detail
- Interaction checker for a whole prescription
Try Pro+ free for 7 days on the web. No card needed.
Other interactions of Indacaterol-glycopyrronium
Other interactions of Encorafenib
Frequently asked questions
Can I take Encorafenib with Indacaterol-glycopyrronium?
MediHelp rates the interaction as moderate. Encorafenib and Indacaterol-glycopyrronium can affect each other. The combination is often manageable, but it may need a change of dose, a change of timing, or extra checks while both are taken. Encorafenib can prolong the QT interval in a dose-dependent way. Indacaterol may add to repolarization effects and reduce potassium, so arrhythmia risk may increase.
How serious is the interaction between Encorafenib and Indacaterol-glycopyrronium?
MediHelp rates it moderate, on a four-level scale (minor, moderate, major, contraindicated) based on published labels and references. What to do, in brief: Monitor ECG and electrolytes during encorafenib therapy, and correct potassium and magnesium abnormalities. Reduce or hold encorafenib if QTc becomes markedly prolonged.
What other medicines interact with Indacaterol-glycopyrronium?
MediHelp also lists interactions of Indacaterol-glycopyrronium with, for example, Amisulpride, Arformoterol, Arsenic trioxide. The full list is on the Indacaterol-glycopyrronium page.
Full monographs, dosing and an interaction checker in the MediHelp app
Open the complete reference, check multi-drug interactions and use dosing tools in the MediHelp app.
